Tbe 2',3'-dideoxy analogue of the potent A 1 receptor agonist, N 6 -cyclohexyladenosine (CHA), was synthesized as a potential antagonist for the A 1 adenosine receptor. In sturlies on adenylate cyclase 2',3'-dideoxy-N 6 -cyclohexyladenosine (ddCHA) did not show agonist properties at A 1 or at A 2 receptors. However, it antagonized the inhibition by R-PIA of adenylate cyclase activity of fat cell membranes via A 1 receptors with a Ki value of 13 .uM. ddCHA competed for the binding of the selective A 1 receptor antagonist, [ 3 HJ8-cyclopentyl-1,3-dipropylxantbine
I. Introduction
Adenosine regulates a large variety of physiological functions inclu<Jing the nervous and cardiovascular systems (reviewed in Gerlach and Becker, 1987) . In general, it appears to represent a negative feed-back mediater, which serves to restore a balance · between metabolic supply and demand (Newby, 1984) . Most of its effects are mediated through specific_ membrane-bound receptors (reviewed in Lohse et al., 1988b) . These receptors have been subdivided on biochemical and pharmacological grounds into A 1 and A 2 * To whom all correspondence should be addressed:
Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, D-6900 Heidelberg, F.R.G. subtypes, of which the A 2 receptor mediates Stimulation of adenylate cyclase, whereas the A 1 receptor mediates inhibition of adenylate cyclase and in sorne cell types opening of K + channels. The two subtypes are generally defined by their different affinities for agonists, with R-N 6 -phenylisopropyladenosine (R-PIA) being more potent than 5'-N-ethylcarboxamidoadenosine (NECA) at A 1 receptors but being less potent at A 2 receptors (Londos et al., 1980) , whereas methylxanthines such as theophylline are antagonists with equal affinity for both subtypes.
The structure-activity relationships at the A 1 receptor have been investigated by many authors using radioligand binding experiments and tests of receptor-mediated functions (see for example Rarnilton et al., 1985; Schwabeet al., 1985; Daly et al., 1986; Cristalli et al., 1988) . These sturlies have led to the development of agonists and antagonists with greater than 1000-fold selectivity for the A 1 receptor (Cristalli et al., 1988; Bruns et al., 1987; Lohse et al., 1987) . However, much less is known about the requirements foragonist activity at the A 1 receptor. Sturlies with adenine (Ebert and Schwabe, 1973) , 9-substituted adenine derivatives (Ukena et al., 1987) and ribose-modified adenosine analogues (Trost and Stock, 1977; Taylor et al., 1986 ) have pointed to the importance of the ribose moiety both for binding affinity and agonist effects .. In the present study we report that removal of the 2'-and 3' -hydroxy groups of the potent full A 1 receptor agonist, N 6 -cyclohexyladenosine (CHA), is sufficient to completely abolish its agonist activity.
Materials and methods
The synthesis of 2',3'-ß-dideoxy-N 6 -cyclohexyladenosine ( ddCHA) and its a-anomer is described elsewhere (Diekmann, 1986) . 8-Cyclopentyl-1,3-[3H)dipropylxanthine ([ 3 H]DPCPX) was prepared as described previously (Lohse et al., 1987 , commercially available from Amersham).
[ a-32 P]A TP was obtained from Amersham Buchler, Braunschweig, FRG, and purified as described earlier (Lohse et al., 1988a ). a-Adenosine was purchased from Sigma, Deisenhofen, FRG. Deoxycoformycine was a kind gift from Prof. Osswald, Gödecke, Freiburg, FRG.
Membranes from rat brain, rat fat cells and human platelets were prepared as outlined earlier (Lohse et al., 1987; Klotzet al., 1985) . The adenylate cyclase activity of rat fat cell membranes and human platelet membranes was determined as described by Klotz et al. (1985) . Binding of [ 3 H]DPCPX to rat brain membranes was measured as reported recently (Lohse et al., 1987) . For binding assays involving adenosine as a competitor, membranes were pretreated with 0.2 U /ml adenosine deaminase as usual (Lohse et al., 1984) and the enzyme activity was blocked by the addition of 100 nM deoxycoformycine. The A 2 receptors of human platelet membranes were solubilized and separated from non-receptor [ 3 H)NECA binding sites by gel filtration. [ 3 HJ NECA binding to the A 2 receptors was measured using pooled fractions containing the A 2 receptors (Lohse et al., 1988a) .
Concentration-response curves were fhted to a modified Hill equation as described earlier (Lohse et al., 1986) , and radioligand binding data were analyzed with the programme SCTFIT (De Lean et al., 1982) . All curve-fitting procedures were carried out by using non-linear regression.
Results
The effects of ddCHA on adenosine receptors were investigated in adenylate cyclase experiments in which rat fat cell membranes were used as a model for the A 1 receptor and human platelet membranes were used as a model for the A 2 receptor. ddCHA did not display any agonist activity in either model in concentrations up to 1 mM. However, 100 .uM ddCHA shifted the R-PIA inhibition curve for rat fat cell membrane adenylate cyclase to the right in a parallel manner, indicating competitive antagonism ( fig. 1) 
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CONCENTRATION OF R-PIA !Ml Fig. 1 (Lohse et al., 1984) .
The a-anomer of ddCHA was somewhat less potent than ddCHA at A 1 receptors but was slightly morepotent at A 2 receptors. This finding is in marked cantrast to the pronounced stereoselectivity of adenosine receptors for adenosine and its a·anomer ( fig. 2) . Since binding assays with adenosine require the inactivation of adenosine deaminase, such experiments can only yield apparent Ki values due to the presence of endogenaus adenosine. Based on these values, the rat brain A 1 receptor showed greater than 1000-fold preference for adenosine compared to a-adenosine, whereas ddCHA was only 3 to 4 times more potent than a-ddCHA. Similarly, the binding of 
Discussion
CHA is a potent full agonist at A 1 receptors (Cristalli et al., 1988) . Removal of the 2'-and 3' -hydroxy groups results not only in a decrease of affinity, which is more marked for the A 1 than for the A 2 receptor, but also in a complete loss of agonist activity. Thus, ddCHA isapure antagonist at both adenosine receptor subtypes, with a 20-to 30-fold selectivity for the A 1 receptor. Removal of the 3'-hydroxy group from R-PIA has been shown to result only in a moderate loss of affinity and the retention of at least partial agonist affinity (Taylor et al., 1986) . Removal of the 2'-hydroxy group from adenosine (Trost and Stock, 1977) or R-PIA (Taylor et al., 1986) results in a marked loss of affinity, but some agonist affinity appears to remain (Trost and Stock, 1977) . At the A 2 receptor of human fibroblasts, 3' -deoxyadenosine has been reported to act as a partial agonist and non-competitive inhibitor of the adenosine-induced increase of cAMP and 2' -deoxyadenosine has been reported to act as a non-competitive inhibitor (Bruns, 1980) . In addition to the loss of agonist activity, the removal of the two hydroxy residues completely abolishes the stereoselective recognition of the ß-versus the a-glycosidic bond by both adenosine receptor subtypes. It seems likely, therefore, that the rest of the ribose moiety does not markedly contribute to receptor binding. This hypothesis is supported by the relatively high affinity reported for N 6 -cyclohexyl-9-methyladenine (Ukena et al., 1987) .
In summary, our results show that the 2'-and 3' -hydroxy groups are essential for agonist activity and for the recognition of the ß-versus the aanomer at adenosine receptors. ddCHA is an adenosine derivative that is an A 1 -selective antagonist, and may be a useful tool in the investigation of the ligand binding site of the A 1 adenosine receptor.
